Xenon Ebit Per Revenue vs Current Deferred Revenue Analysis

XENE Stock

USD 41.88 0.17 0.40%

Xenon Pharmaceuticals financial indicator trend analysis is more than just analyzing Xenon Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Xenon Pharmaceuticals is a good investment. Please check the relationship between Xenon Pharmaceuticals Ebit Per Revenue and its Current Deferred Revenue accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.

Ebit Per Revenue vs Current Deferred Revenue

Ebit Per Revenue vs Current Deferred Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Xenon Pharmaceuticals Ebit Per Revenue account and Current Deferred Revenue. At this time, the significance of the direction appears to have fragmental relationship.

The correlation between Xenon Pharmaceuticals' Ebit Per Revenue and Current Deferred Revenue is 0.51. Overlapping area represents the amount of variation of Ebit Per Revenue that can explain the historical movement of Current Deferred Revenue in the same time period over historical financial statements of Xenon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Xenon Pharmaceuticals' Ebit Per Revenue and Current Deferred Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit Per Revenue of Xenon Pharmaceuticals are associated (or correlated) with its Current Deferred Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Current Deferred Revenue has no effect on the direction of Ebit Per Revenue i.e., Xenon Pharmaceuticals' Ebit Per Revenue and Current Deferred Revenue go up and down completely randomly.

Correlation Coefficient

0.51

Relationship Direction	Positive
Relationship Strength	Weak

View All Relationships

Ebit Per Revenue

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Most indicators from Xenon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Xenon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.At present, Xenon Pharmaceuticals' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 2.2 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 2.65.

Xenon Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Common Stock Shares Outstanding		0.97	0.43	0.99	0.3	0.97	-0.46	0.96	0.01	-0.59	-0.98	0.98	0.66	0.87	0.84	0.76	0.96	0.52	0.98	-0.27	0.96	0.7	0.03	0.65	-0.45	0.96
Total Assets	0.97		0.37	0.98	0.3	1.0	-0.36	0.99	0.08	-0.71	-0.98	0.97	0.77	0.92	0.79	0.66	0.98	0.44	0.98	-0.2	0.93	0.76	0.08	0.65	-0.36	0.98
Short Long Term Debt Total	0.43	0.37		0.44	0.28	0.38	-0.68	0.27	-0.1	-0.05	-0.44	0.37	0.15	0.31	0.4	0.66	0.38	0.07	0.45	-0.4	0.51	0.26	-0.07	0.67	-0.61	0.38
Other Current Liab	0.99	0.98	0.44		0.37	0.98	-0.44	0.97	0.1	-0.62	-0.99	0.97	0.7	0.9	0.85	0.74	0.96	0.5	0.98	-0.26	0.95	0.76	0.08	0.63	-0.43	0.96
Total Current Liabilities	0.3	0.3	0.28	0.37		0.26	0.16	0.31	0.84	-0.06	-0.35	0.35	0.11	0.28	0.23	0.27	0.3	0.18	0.26	0.32	0.28	0.58	0.8	0.03	0.2	0.3
Total Stockholder Equity	0.97	1.0	0.38	0.98	0.26		-0.4	0.99	0.05	-0.71	-0.98	0.97	0.77	0.92	0.8	0.66	0.98	0.45	0.99	-0.24	0.93	0.74	0.03	0.67	-0.39	0.98
Other Liab	-0.46	-0.36	-0.68	-0.44	0.16	-0.4		-0.32	0.45	0.1	0.41	-0.39	-0.15	-0.27	-0.67	-0.48	-0.39	-0.28	-0.5	0.92	-0.55	0.0	0.67	-0.77	0.94	-0.39
Property Plant And Equipment Net	0.96	0.99	0.27	0.97	0.31	0.99	-0.32		0.14	-0.71	-0.96	0.97	0.76	0.89	0.82	0.62	0.98	0.51	0.97	-0.18	0.93	0.78	0.09	0.59	-0.31	0.98
Current Deferred Revenue	0.01	0.08	-0.1	0.1	0.84	0.05	0.45	0.14		-0.14	-0.05	0.08	0.13	0.05	0.04	-0.1	0.1	0.15	-0.01	0.47	0.01	0.5	0.8	-0.29	0.5	0.09
Net Debt	-0.59	-0.71	-0.05	-0.62	-0.06	-0.71	0.1	-0.71	-0.14		0.62	-0.54	-0.99	-0.58	-0.53	-0.37	-0.74	-0.55	-0.65	0.04	-0.54	-0.66	-0.03	-0.43	0.12	-0.74
Retained Earnings	-0.98	-0.98	-0.44	-0.99	-0.35	-0.98	0.41	-0.96	-0.05	0.62		-0.97	-0.7	-0.93	-0.79	-0.75	-0.95	-0.44	-0.98	0.21	-0.93	-0.74	-0.1	-0.64	0.4	-0.95
Accounts Payable	0.98	0.97	0.37	0.97	0.35	0.97	-0.39	0.97	0.08	-0.54	-0.97		0.61	0.91	0.79	0.65	0.95	0.39	0.97	-0.23	0.95	0.7	0.09	0.63	-0.39	0.95
Cash	0.66	0.77	0.15	0.7	0.11	0.77	-0.15	0.76	0.13	-0.99	-0.7	0.61		0.64	0.58	0.47	0.79	0.56	0.72	-0.05	0.61	0.7	0.05	0.47	-0.17	0.79
Non Current Assets Total	0.87	0.92	0.31	0.9	0.28	0.92	-0.27	0.89	0.05	-0.58	-0.93	0.91	0.64		0.61	0.52	0.84	0.13	0.89	-0.15	0.79	0.65	0.1	0.5	-0.26	0.84
Non Currrent Assets Other	0.84	0.79	0.4	0.85	0.23	0.8	-0.67	0.82	0.04	-0.53	-0.79	0.79	0.58	0.61		0.63	0.83	0.71	0.84	-0.58	0.86	0.62	-0.21	0.63	-0.57	0.83
Long Term Debt	0.76	0.66	0.66	0.74	0.27	0.66	-0.48	0.62	-0.1	-0.37	-0.75	0.65	0.47	0.52	0.63		0.68	0.52	0.73	-0.15	0.73	0.61	0.08	0.55	-0.49	0.69
Cash And Short Term Investments	0.96	0.98	0.38	0.96	0.3	0.98	-0.39	0.98	0.1	-0.74	-0.95	0.95	0.79	0.84	0.83	0.68		0.57	0.98	-0.22	0.94	0.78	0.06	0.68	-0.38	1.0
Net Receivables	0.52	0.44	0.07	0.5	0.18	0.45	-0.28	0.51	0.15	-0.55	-0.44	0.39	0.56	0.13	0.71	0.52	0.57		0.48	-0.2	0.51	0.48	-0.02	0.33	-0.26	0.57
Common Stock Total Equity	0.98	0.98	0.45	0.98	0.26	0.99	-0.5	0.97	-0.01	-0.65	-0.98	0.97	0.72	0.89	0.84	0.73	0.98	0.48		-0.32	0.97	0.71	-0.02	0.72	-0.5	0.98
Non Current Liabilities Total	-0.27	-0.2	-0.4	-0.26	0.32	-0.24	0.92	-0.18	0.47	0.04	0.21	-0.23	-0.05	-0.15	-0.58	-0.15	-0.22	-0.2	-0.32		-0.37	0.2	0.82	-0.6	0.85	-0.22
Other Current Assets	0.96	0.93	0.51	0.95	0.28	0.93	-0.55	0.93	0.01	-0.54	-0.93	0.95	0.61	0.79	0.86	0.73	0.94	0.51	0.97	-0.37		0.66	-0.05	0.74	-0.55	0.94
Other Stockholder Equity	0.7	0.76	0.26	0.76	0.58	0.74	0.0	0.78	0.5	-0.66	-0.74	0.7	0.7	0.65	0.62	0.61	0.78	0.48	0.71	0.2	0.66		0.49	0.26	0.05	0.78
Total Liab	0.03	0.08	-0.07	0.08	0.8	0.03	0.67	0.09	0.8	-0.03	-0.1	0.09	0.05	0.1	-0.21	0.08	0.06	-0.02	-0.02	0.82	-0.05	0.49		-0.36	0.65	0.06
Property Plant And Equipment Gross	0.65	0.65	0.67	0.63	0.03	0.67	-0.77	0.59	-0.29	-0.43	-0.64	0.63	0.47	0.5	0.63	0.55	0.68	0.33	0.72	-0.6	0.74	0.26	-0.36		-0.81	0.68
Preferred Stock Total Equity	-0.45	-0.36	-0.61	-0.43	0.2	-0.39	0.94	-0.31	0.5	0.12	0.4	-0.39	-0.17	-0.26	-0.57	-0.49	-0.38	-0.26	-0.5	0.85	-0.55	0.05	0.65	-0.81		-0.38
Total Current Assets	0.96	0.98	0.38	0.96	0.3	0.98	-0.39	0.98	0.09	-0.74	-0.95	0.95	0.79	0.84	0.83	0.69	1.0	0.57	0.98	-0.22	0.94	0.78	0.06	0.68	-0.38

Click cells to compare fundamentals

Xenon Pharmaceuticals Account Relationship Matchups

Xenon Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	25.9M	34.5M	43.6M	60.5M	66.9M	70.2M
Total Assets	147.7M	189.2M	572.0M	754.1M	964.8M	1.0B
Short Long Term Debt Total	16.5M	3.3M	8.3M	10.4M	10.9M	10.0M
Other Current Liab	6.3M	7.8M	9.9M	13.7M	17.4M	18.2M
Total Current Liabilities	43.4M	14.8M	14.3M	22.7M	27.3M	17.3M
Total Stockholder Equity	92.0M	171.4M	550.0M	721.5M	927.9M	974.3M
Property Plant And Equipment Net	2.6M	6.9M	12.5M	16.9M	18.8M	19.8M
Net Debt	(8.3M)	(41.7M)	(167.4M)	(46.8M)	(137.7M)	(130.9M)
Retained Earnings	(249.7M)	(278.5M)	(357.4M)	(482.7M)	(665.1M)	(631.9M)
Accounts Payable	2.5M	3.0M	3.8M	8.5M	8.6M	9.0M
Cash	24.8M	45.0M	175.7M	57.2M	148.6M	156.1M
Non Current Assets Total	2.8M	7.4M	13.0M	153.8M	319.8M	335.8M
Non Currrent Assets Other	2.6M	7.4M	8.1M	7.8M	7.4M	7.8M
Cash And Short Term Investments	141.4M	177.0M	551.8M	592.1M	638.1M	670.0M
Net Receivables	813K	1.8M	2.8M	986K	874K	872.3K
Common Stock Total Equity	294.2M	397.7M	783.2M	1.1B	1.2B	1.3B
Liabilities And Stockholders Equity	147.7M	189.2M	572.0M	754.1M	964.8M	1.0B
Non Current Liabilities Total	12.3M	3.1M	7.7M	9.9M	9.6M	7.2M
Other Current Assets	2.7M	3.0M	4.5M	7.2M	6.0M	6.3M
Other Stockholder Equity	40.6M	45.4M	117.5M	142.1M	156.8M	164.6M
Total Liab	55.7M	17.8M	22.0M	32.6M	36.9M	27.2M
Total Current Assets	144.9M	181.8M	559.0M	600.3M	645.0M	677.2M
Common Stock	294.2M	397.7M	783.2M	1.1B	1.4B	1.5B
Property Plant Equipment	1.7M	3.6M	4.5M	6.5M	7.5M	7.8M
Net Tangible Assets	84.2M	163.6M	542.3M	721.5M	829.7M	871.2M
Other Assets	238K	523K	465K	143.7M	306.2M	321.5M
Short Term Investments	116.6M	132.0M	376.1M	534.8M	489.4M	513.9M
Retained Earnings Total Equity	(249.7M)	(278.5M)	(357.4M)	(482.7M)	(434.5M)	(412.7M)
Capital Surpluse	40.6M	45.4M	117.5M	142.1M	163.4M	171.6M
Net Invested Capital	99.8M	163.6M	542.3M	721.5M	927.9M	974.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Xenon Pharmaceuticals is a strong investment it is important to analyze Xenon Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Xenon Pharmaceuticals' future performance. For an informed investment choice regarding Xenon Stock, refer to the following important reports:

How To Invest In Xenon

Details

Is Xenon Stock a good investment?

Details

What is Xenon Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Xenon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Xenon Stock refer to our How to Trade Xenon Stock guide.

You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Xenon Pharmaceuticals. If investors know Xenon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Xenon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.81)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.19)

Return On Equity

(0.27)

The market value of Xenon Pharmaceuticals is measured differently than its book value, which is the value of Xenon that is recorded on the company's balance sheet. Investors also form their own opinion of Xenon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Xenon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Xenon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Xenon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Xenon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Xenon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Xenon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Xenon Ebit Per Revenue vs Current Deferred Revenue Analysis

Ebit Per Revenue vs Current Deferred Revenue

Ebit Per Revenue vs Current Deferred Revenue Correlation Analysis

Correlation Coefficient

Ebit Per Revenue

Current Deferred Revenue

Xenon Pharmaceuticals fundamental ratios Correlations

Xenon Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Xenon Pharmaceuticals fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Current Liab	+ 0.99	Common Stock Shares Outstanding
Property Plant And Equipment Net	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Total Stockholder Equity
Common Stock Total Equity	+ 0.99	Total Stockholder Equity

Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Other Current Liab
Common Stock Total Equity	- 0.98	Retained Earnings
Retained Earnings	- 0.98	Total Stockholder Equity
Retained Earnings	- 0.98	Total Assets
Retained Earnings	- 0.98	Common Stock Shares Outstanding